AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aquestive Therapeutics: Analysts Increase Price Target to $10.51
ByAinvest
Monday, Nov 17, 2025 5:55 pm ET1min read
Aquestive Therapeutics' (AQST) average one-year price target has been revised to $10.51/share, a 14.80% increase from the prior estimate of $9.15/share. This is based on analysts' targets ranging from $8.08 to $15.75/share. The average target represents a 94.92% increase from the latest closing price of $5.39/share. The number of funds reporting positions in AQST has increased to 251, with institutional ownership rising by 33.78% to 70,713K shares. The put/call ratio of AQST is 0.26, indicating a bullish outlook.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet